Sangamo Biosciences (SGMO) has disclosed a new risk, in the Regulation category.
Sangamo Biosciences faces a precarious financial future, as its cash reserves are projected to sustain operations only until the third quarter of 2024. Despite active efforts to raise additional capital, the company’s inability to secure further funding has compelled it to consider bankruptcy protection as a possible recourse. Should Sangamo file for bankruptcy, the company’s operational continuity, product development, and overall survival would be fraught with uncertainty, including potential liquidation. This scenario poses a stark risk for common stockholders who may confront total loss of their investment.
The average SGMO stock price target is $2.00, implying 154.74% upside potential.
To learn more about Sangamo Biosciences’ risk factors, click here.
